Company intelligence / Profile preview

VisioNetx

Philadelphia, PA, USA

Ownership: Private
Employees: ~15
Development stage: Other

Overview

VisioNetx is a biotechnology company focused on developing next-generation gene therapies for inherited retinal diseases. The company was co-founded by Dr. Jean Bennett and Dr. Albert Maguire, the pioneering researchers who developed Luxturna, the first FDA-approved gene therapy for an inherited disease. VisioNetx utilizes proprietary AAV-based platforms to deliver functional genes to the retina, aiming to treat conditions such as Leber Congenital Amaurosis. Their lead program, VNX-101, targets GUCY2D-related LCA1 and is currently in pre-clinical development. Based in Philadelphia, the company leverages deep expertise in ocular genetics to restore and preserve vision in patients with rare genetic disorders.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Partnerships

University of Pennsylvania

Beyond the preview

Go deeper on VisioNetx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisioNetx.

Explore the full profile